Avtal | $24,000,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Claros | $30,000,000 | (Mar 20, 2026)
Evonetix Ltd
United Kingdom
- Cambridge, England
- 10/02/2023
- Series B
- $24,000,000
We are a Cambridge-based company developing a radically different approach to gene synthesis. Our desktop DNA synthesis platform will provide the ability to synthesise DNA at unprecedented accuracy, scale and speed, accelerating scientists' ability to use synthetic biology on a scale not currently possible.
- Industry Research Services
- Website https://www.evonetix.com/
- LinkedIn https://www.linkedin.com/company/evonetix-ltd/
Related People
Colin McCrackenFounder
United Kingdom -
Cambridge, England
Accomplished life science Executive with global experience involving both start-up and growth organizations. Forthright, confident, creative, inspirational leader who is used to fast changing working environments. Consistent high performer, that works closely with people constantly striving to get things done. A clear thinker, that concentrates on the detail, bringing pragmatism and realism to all aspects of his work. A strong motivator and team builder.
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Edra | $30,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)
SetSale | $2,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)